Back to Research Hub
Insmed Incorporated
INSM
$99.04+4.87 (+5.17%)
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
StreetsValue research for Insmed Incorporated (INSM)
Members get the full report for Insmed Incorporated: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.